Lorlatinib as a treatment for ALK-positive lung cancer
Kazuyoshi Baba, Yasushi Goto
Abstract
Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a treatment for ALK-positive lung cancer. This review provides information regarding the pharmacology and clinical features of lorlatinib, including its efficacy and associated adverse events. Pivotal clinical trials are discussed along with the current status of lorlatinib as a treatment for ALK-positive lung cancer and future therapeutic challenges.
Topics & Concepts
Lung cancerMedicineClinical trialTyrosine-kinase inhibitorTreatment of lung cancerAnaplastic lymphoma kinaseCancerCancer treatmentAdverse effectCancer researchTyrosine kinaseInternal medicineReceptorMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment